Pharmacovigilance services for the Pharmaceutical Industry.

Round table and discussion – Differences between Phase III and Phase IV Drug Safety and Pharmacovigilance – University of Valladolid

  • November 12, 2022

José Alberto Ayala Ortiz, PVpharm CEO, will participate together with Andrea Álvarez, QPPV of FAES FARMA in a Round table and discussion about "Differences between Phase III and Phase IV Drug Safety and Pharmacovigilance" organized by the University of Valladolid. The conference will be held on 17th November 2022 at 18:00 CET, and it is free of access!! Please join here. PVpharm is also organizing in-house trainings in pharmacovigilance for pharmaceutical companies and CROs, please contact us for further information.

Continue Reading

PVpharm participates in the 2022 European Researchers’ Night

  • September 29, 2022

The European Researchers' Night is a Europe-wide public event, which displays the diversity of science and its impact on citizens' daily lives in fun, inspiring ways. This year, the event will take place in 25 countries on Friday 30 September 2022. The European Researchers' Night aims to: -bring research and researchers closer to the public-promote excellent research projects across Europe and beyond-increase the interest of young people in science and research careers-showcase the impact of researchers’ work on people’s daily lives The European Researchers’ Night attracts each year more than 1 million visitors in Europe and beyond. Juego de la…

Continue Reading

PVpharm provides support to the UCLouvain for COVID-19 phase II study project

  • March 30, 2021

We are happy to announce that PVpharm has been selected to provide safety support for a research project coordinated by the Catholic University of Louvain (UCLouvain) for a COVID-19 Phase II study. PVpharm will be supporting the clinical safety function with pharmacovigilance, report submission, safety report writing, Eudravigilance, CTIS and other PV and administrative related activities. PVpharm is providing support to Sponsors of clinical trials in the EU, please read more about our Pharmacovigilance services at Please contact us with any question

Continue Reading